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Abstract
HLA-DRB1, especially the shared epitope (SE), is strongly associated with rheumatoid arthritis (RA). However, recent studies
have shown that SE is at most weakly associated with RA without anti-citrullinated peptide/protein antibody (ACPA). We
have recently reported that ACPA-negative RA is associated with specific HLA-DRB1 alleles and diplotypes. Here, we
attempted to detect genetically different subsets of ACPA-negative RA by classifying ACPA-negative RA patients into two
groups based on their positivity for rheumatoid factor (RF). HLA-DRB1 genotyping data for totally 954 ACPA-negative RA
patients and 2,008 healthy individuals in two independent sets were used. HLA-DRB1 allele and diplotype frequencies were
compared among the ACPA-negative RF-positive RA patients, ACPA-negative RF-negative RA patients, and controls in each
set. Combined results were also analyzed. A similar analysis was performed in 685 ACPA-positive RA patients classified
according to their RF positivity. As a result, HLA-DRB1*04:05 and *09:01 showed strong associations with ACPA-negative RF-
positive RA in the combined analysis (p = 8.861026 and 0.0011, OR: 1.57 (1.28–1.91) and 1.37 (1.13–1.65), respectively). We
also found that HLA-DR14 and the HLA-DR8 homozygote were associated with ACPA-negative RF-negative RA (p = 0.00022
and 0.00013, OR: 1.52 (1.21–1.89) and 3.08 (1.68–5.64), respectively). These association tendencies were found in each set.
On the contrary, we could not detect any significant differences between ACPA-positive RA subsets. As a conclusion, ACPA-
negative RA includes two genetically distinct subsets according to RF positivity in Japan, which display different associations
with HLA-DRB1. ACPA-negative RF-positive RA is strongly associated with HLA-DRB1*04:05 and *09:01. ACPA-negative RF-
negative RA is associated with DR14 and the HLA-DR8 homozygote.
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Introduction
Rheumatoid arthritis (RA) is the most common cause of chronic
arthritis worldwide and results in severe joint destruction [1].
Genetic and environmental factors have been shown to be
associated with its onset [2–3]. Among the susceptibility genes to
RA, HLA-DRB1 has been shown to be the strongest genetic
determinant of RA susceptibility, and its association with RA
susceptibility has been repeatedly shown to be independent of
ethnicity [4–5]. A common amino acid sequence extending from
the 70th to 74th in the HLA-DRb chain, which is known as the
‘‘shared epitope (SE)’’, is considered to be the reason for the
association between HLA-DRB1 and RA, and the association
between the SE and RA has been reported to be ethnicity-
independent [6–8]. However, recent studies have shown that the
SE is strongly associated with RA patients who have anti-
citrullinated peptide/protein antibodies (ACPA), which is a highly
specific marker of RA [9], but that it is not or only weakly
associated with RA without ACPA [7,10–11]. Among the various
HLA-DRB1 alleles, HLA-DR3 [12] and HLA-DR13 [13] were
reported to be associated with ACPA-negative RA in populations
of European descent, but these results were not confirmed in a
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meta-analysis of a large Caucasian cohort [8]. In Asian
populations, we recently reported that DRB1*12:01 is a HLA-
DRB1 susceptibility allele for ACPA-negative RA in Japanese
populations and that DRB1*04:05, the most common SE allele in
Japanese, and *14:03 showed moderate associations with ACPA-
negative RA susceptibility [14]. We also reported that
DRB1*15:02 and *13:02 displayed protective associations with
ACPA-negative RA and that being homozygous for HLA-DR8
was associated with ACPA-negative RA susceptibility. While a
very small Japanese study suggested that HLA-DRB1*09:01 is
associated with ACPA-negative RA [15], our study did not detect
a significant association between them. These findings suggest that
ACPA-negative RA is genetically different from ACPA-positive
RA in terms of its associations with HLA-DRB1 alleles. While
some specific alleles and diplotypes seem to be associated with
ACPA-negative RA, the genetic characteristics of ACPA-negative
RA have not been fully elucidated. Recently, UK group reported
that SE is associated with ACPA-negative RF-positive RA in UK
population [16]. However, whether this is true to other population
is uncertain. Moreover, the associations of other alleles than SE
with subgroups of ACPA-negative RA have never been reported.
Here, we show that when we classified ACPA-negative RA into
two subsets based on rheumatoid factor (RF) positivity, we were
able to clearly distinguish them from each other according to their
associations with HLA-DRB1 alleles, not only with SE, but with
other alleles. We also compared ACPA-positive RA patients based
on their RF positivity to examine whether we can apply this
classification to ACPA-positive RA.
Results
HLA-DRB1 Alleles Associated with ACPA-negative RF-
positive RA
We compared 179 ACPA-negative RF-positive RA with 1508
controls in collection 1 for their frequency of HLA-DRB1 alleles,
followed by comparison of 267 ACPA-negative RF-positive RA
with 500 controls in collection 2. Significant association was
evaluated in the combined analysis. Regarding HLA-DRB1 alleles
that were previously shown to be associated with ACPA-negative
RA, we found that all of the alleles, namely, HLA-DRB1*12:01,
*04:05, *13:02, *14:03, and *15:02 showed association tendency
with ACPA-negative RF-positive RA in the combined study
(Table 1). Interestingly, HLA-DRB1*04:05 (p = 8.861026, odds
ratio (OR): 1.57) showed the strongest association, while its
association with entire ACPA-negative RA was moderate in the
previous study. When we analyzed the associations of the SE, we
found that it displayed a significant association (p= 0.00013, OR:
1.37). HLA-DRB1*04:05 was responsible for most of the
association of SE because none of the other SE alleles showed
significant associations with ACPA-negative RF-positive RA. We
also found that HLA-DRB1*09:01, which was not associated with
ACPA-negative RA as a single allele, was found to be significantly
associated with ACPA-negative RF-positive RA (p= 0.0011, OR:
1.37). Importantly, these association tendencies written above
were observed in both collections (Table 1). Logistic regression
analysis was carried out to examine whether the susceptibility
associations were dependent on a lack of protective alleles or vice
versa. As a result, it was demonstrated that HLA-DRB1*04:05,
*09:01, and *12:01 showed significant associations (p,0.0005),
while the associations of HLA-DRB1*14:03, *13:02, and *15:02
were moderate to suggestive (Table S1). Next, we analyzed the
dosage effects of the alleles and found that the association between
HLA-DRB1*09:01 and ACPA-negative RF-positive RA showed a
clear dosage effect (Figure S1). HLA-DRB1*12:01 also showed a
dosage effect (data not shown due to small number). HLA-
DRB1*04:05 did not show a dosage effect, suggesting that the
effect of HLA-DRB1*04:05 on the predisposition to ACPA-
negative RF-positive RA is a dominant effect.
HLA-DRB1 Alleles Associated with ACPA-negative RF-
negative RA
Next we compared 274 ACPA-negative RF-negative RA with
1,508 controls, followed by comparison between 234 ACPA-
negative RF-negative RA and 500 controls. Interestingly, we did
not observe association of HLA-DRB1*04:05 and *09:01 with
ACPA-negative RF-negative RA, while HLA-DRB1*12:01,
*13:02, *14:03, and *15:02 were moderately associated with
ACPA-negative RF-negative RA (Table 2). The SE was not
associated with ACPA-negative RF-negative RA. DR14 was found
to be significantly associated with ACPA-negative RF-negative RA
and HLA-DRB1*14:03 and *14:06 comprised the association of
HLA-DR14 (Table S2). These association tendencies in ACPA-
negative RF-negative RA were observed in both sets (Table 2).
Logistic regression analysis confirmed that none of the associations
were mutually dependent and that the association of DR14
remained significant (p = 0.00069, Table S3). DR14 could not be
evaluated the dosage effect because neither the cases nor controls
included DRB1*14:03 or *14:06 homozygotes or the DRB1*14:03
and *14:06 diplotype.
HLA Diplotype Analysis: DR8 Homozygote and *12:01/
*09:01 Diplotype
As we previously showed that the DR8 homozygote was
significantly associated with susceptibility to ACPA-negative RA,
we analyzed its associations with ACPA-negative RF-positive RA
and RF-negative RA. As a result, we found that the HLA-DR8
homozygote is exclusively associated with ACPA-negative RF-
negative RA in the combined study (p = 0.00013, OR: 3.08 for
ACPA-negative RF-negative RA, Table 2; p= 0.86, OR: 1.08 for
ACPA-negative RF-positive RA, Table 1). The effect of DR8 on
the susceptibility to ACPA-negative RF-negative RA was not dose-
dependent (OR: 1.04 for HLA-DR8 heterozygote).
We also found that the combination of HLA-DRB1*12:01 and
*09:01, the diplotype that was most strongly associated with
susceptibility to ACPA-negative RA in the previous study, was
especially strongly associated with ACPA-negative RF-positive RA
(p= 5.061026, OR: 4.97 for ACPA-negative RF-positive RA;
p= 0.040, OR: 2.46 for ACPA-negative RF-negative RA).
We found that the similar associations were seen between the
alleles/diplotypes and ACPA-negative RF-positive erosive RA and
ACPA-negative RF-negative erosive RA (except for that between
HLA-DRB1*12:01 and the ACPA-negative RF-negative subset),
even though the number of patients was limited (Table S4).
Comparison between ACPA-negative RF-positive RA and
ACPA-negative RF-negative RA
To compare the usage of HLA-DRB1 allele between ACPA-
negative RF-positive RA and ACPA-negative RF-negative RA, we
directly compared the allele and diplotype frequencies between the
two groups (Table 3). As expected, HLA-DRB1*09:01 and *04:05
showed significant differences in their frequencies between the two
subsets (p = 0.0018 and 0.0034, respectively). The SE was more
common in the ACPA-negative RF-positive RA patients
(p = 0.0047), whereas DR14 was more prevalent in the ACPA-
negative RF-negative RA patients (p = 0.028). The DR8 homozy-
gote was more frequently seen in the ACPA-negative RF-negative
RA patients than in the ACPA-negative RF-positive RA patients
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(p = 0.021). When we applied logistic regression analysis to the
HLA-DRB1*09:01, *04:05, and HLA-DR14, their associations
were revealed to be significant and do not depend on each other
(p = 0.00067 and 0.00072, respectively, Table S5), except for that
of DR14 (p = 0.30).
Comparison between ACPA-positive RF-positive RA and
ACPA-positive RF-negative RA
Next, we analyzed whether these allele usage differences are also
seen in ACPA-positive RA. We collected data about the HLA-
DRB1 genotypes of 154 ACPA-positive RF-negative RA patients
and 531 ACPA-positive RF-positive RA patients. As the SE and
HLA-DRB1*09:01 were found to be associated with ACPA-
positive RA, we analyzed the differences in the frequencies of these
alleles [17]. In comparison with the healthy controls, SE and
HLA-DRB1*09:01 were associated with a predisposition to
ACPA-positive RF-positive RA as well as ACPA-positive RF-
negative RA and displayed comparable odds ratios in logistic
regression analysis (Table 4). No HLA-DRB1 alleles showed a
strong specific association with a particular subset. When we
directly compared the two subsets of ACPA-positive RA, no alleles
displayed significant associations (Figure 1, Table S6). However,
whether the two subsets of ACPA-positive RA share most of HLA-
DRB1 susceptibility associations is inconclusive due to the small
number of RF-negative subset.
Discussion
In this study, we demonstrated that classifying Japanese ACPA-
negative RA patients based on their RF positivity successfully
divided them into two genetically different subsets, which
displayed different associations with HLA-DRB1. We showed
that HLA-DRB1*09:01 and *04:05, strong susceptibility alleles to
ACPA-positive RA, were also associated with ACPA-negative RF-
positive subset, and that DR14 and the DR8 homozygote were
associated only with the ACPA-negative RF-negative subset
(Figure 1). Since the titer of RF fluctuates along with disease
activity much more than that of ACPA, we were very careful to
take the maximum RF titer when multiple titers were available for
a particular patient, in order to prevent the RF positive subset
from being contaminated with RF negative RA patients. The
Recent UK population study reported the association of SE with
ACPA-negative RF-positive RA [16]. Our study not only
confirmed this association in Japanese RA, but also showed that
the association of SE with ACPA-negative RF-positive RA is
mainly due to the effect of HLA-DRB1*04:05 and that HLA-
DRB1*09:01, HLA-DR14, and homozygote of HLA-DR8 are
specifically associated with subsets of ACPA-negative RA.
These above-mentioned association tendencies were observed in
the first set and successfully replicated in the second set, indicating
that we can avoid population stratification or sampling bias. The
effect sizes (odds ratio) of the alleles were comparable in each
cohort (Tables 1 and 2) and the associations in the combined
analysis reached significant level, although the p-values in each set
did not reach the significance level due to the limited number of
samples they contained. These data indicate that our results are
reliable, at least in Japanese populations, although further
replication studies including other populations are favorable. In
the current study, we used logistic regression analysis to confirm
independency of associated alleles in each comparison. When we
used relative predispositional effects (RPE) method [18] to stratify
associated alleles, we obtained the similar results to those we
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In our previous study [14], HLA-DRB1*09:01 was not
significantly associated with ACPA-negative RA, in spite of the
association it displayed in combination with HLA-DRB1*12:01.
In the current study, we showed that HLA-DRB1*09:01 displayed
a strong dose-dependent association with ACPA-negative RF-
positive RA, but not with ACPA-negative RF-negative RA. These
findings were confirmed by a direct comparison between the two
subsets. A small study in Japan suggested that HLA-DRB1*09:01
is associated with ACPA-negative RA [15]. Our results suggest
that their study mainly included ACPA-negative RF-positive RA
patients. HLA-DRB1*09:01 was shown to reduce the ACPA titer
in Japanese ACPA-positive RA patients [19–20]. Therefore, HLA-
DRB1*09:01 might increase the titer of RF and decrease that of
ACPA, although our study also showed that HLA-DRB1*09:01 is
associated with ACPA-positive RF-negative RA.
HLA-DRB1*04:05, which is a major component of the SE in
Asians [17], was shown to be significantly associated with ACPA-
negative RA in our previous study. The current study showed that
it is only associated with ACPA-negative RF-positive RA. This
predisposition was also confirmed by direct comparison of the two
subsets. As we could not detect a dosage effect of HLA-
DRB1*04:05, its susceptibility effect might occur in a dominant
manner. It is interesting that of the many SE alleles only HLA-
DRB1*04:05 is associated with ACPA-negative RF-positive RA.
This does not seem to be due to the relatively low frequencies of
the other SE alleles (Table 1). Therefore, the common amino acid
sequence that extends from the 70th to the 74th amino acid of the
HLA-DRb chain might not be important for the development of
ACPA-negative RF-positive RA. As immunization of citrullinated
peptide induced arthritis in HLA-DR4 transgenic mice [21] and
citrullinated peptides were shown to have higher affinity to HLA-
DR4 [22], high affinity of SE to citrullinated antigen is
hypothesized to be the link between SE and RA development.
Our findings may raise possibility of another mechanism of SE in
developing arthritis.
It is quite interesting that HLA-DRB1*04:05 and *09:01,
strongly associated alleles with ACPA-positive RA, are associated
with ACPA-negative RF-positive RA. Although there are genetic
similarities between ACPA-negative RF-positive RA and ACPA-
positive RA, they should be considered to be different subsets as
SE alleles other than HLA-DRB1*04:05 are not associated with
ACPA-negative RF-positive RA and the HLA-DRB1*09:01 and
*12:01 diplotype is strongly associated with ACPA-negative RF-
positive RA.
When we analyzed the HLA-DR14 serotype, it showed a strong
association with ACPA-negative RF-negative RA, largely due to
HLA-DRB1*14:03 and *14:06. When we compared the frequency
of DR14 in each ACPA-negative subset after stratifying the data
according to the presence of HLA-DRB1*09:01 and *04:05,
DR14 did not display a significant effect. In this sense, the specific
association of DR14 with ACPA-negative RF-negative RA needs
to be confirmed.
The HLA-DR8 homozygote displayed an association with
ACPA-negative RA in our previous study [14]. The current study
demonstrated that its association is specific to ACPA-negative RF-
negative RA. As the number of HLA-DR8 homozygote is limited,
further replication is necessary for this association. No association
between the HLA-DR8 and 14 diplotype and susceptibility to
ACPA-negative RF-negative RA was found (data not shown).
It is interesting that HLA-DR14 and HLA-DR8, associated
serotype with ACPA-negative RF-negative RA, were reported
association with psoriatic arthritis [23]. HLA-DR14 is often linked
with HLA-Cw*06, susceptibility serotype to psoriasis arthritis in
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strong association between HLA-Cw*06 and HLA-DR14 is not
observed in Japan (,10%). While psoriatic arthritis is not reported
to be associated with these serotypes in Japan, association between
these serotypes and arthritis is interesting.
It could be argued that ACPA-negative RA includes some
non-RA arthritic diseases such as psoriasis, seronegative spondy-
loarthropathy and other collagen vascular diseases. Thus, we
analyzed the associations between the above-mentioned alleles
and diplotypes with ACPA-negative RA displaying bone erosion
to examine whether the same association patterns were present
in this strictly defined cohort. The typical bone erosions of RA
are rarely seen in other arthritic disorders. As a result, we found
the same associations. Therefore, we are convinced that our
findings were not caused by the contamination of our study
population by patients with other diseases. Since RF sometimes
normalizes after treatment, the RF-negative RA patients whose
RF titers were not measured at multiple points might not have
been RF-negative. So, we re-analyzed our data by excluding the
RA patients for whom consecutive RF titers were not available.
As a result, we found the same tendency of associations for each
allele and diplotype in each subset (data not shown), indicating
that these subsets are stable.
Analysis using ACPA-positive RF-positive RA and ACPA-
positive RF-negative RA patients compared with healthy controls
did not result in distinct differences in HLA-DRB1 association.
The SE is associated with both ACPA-positive RF-positive and
RF-negative RA. HLA-DRB1*09:01 was found to be associated
with both subsets after stratifying the patients according to their
SE alleles. We also did not detect an association between HLA-
DR14 or the HLA-DR8 homozygote and either subset. While 154
ACPA-positive RF-negative RA patients in our study are too small
in number to detect the difference in HLA-DRB1 alleles with weak
effect size between the two ACPA-positive subsets, these results
suggest that there are no big differences in the HLA usage of the
two subsets in ACPA-positive RA. To confirm our results and to
detect possible different frequency of other HLA-DRB1 alleles in
the two ACPA-positive subsets, replication study is necessary.
In the current study, we performed multiple comparisons in
each subset and between subsets. The associations should be
evaluated in the combined analysis with significant level corrected
by Bonferronii’s method and independency of each association
should be evaluated by logistic regression analysis or RPE method.
In this sense, p-values around cut-off level in the combined analysis
should be taken with caution and the associations should be
confirmed by independent study.
We have shown that ACPA-negative RA includes two
genetically distinct subsets in Japanese population: RF-positive
and RF-negative RA. This is the first report in Asians to show that
these subsets are genetically distinct. We have to clarify the clinical
difference between these two subsets. We also have to clarify
whether non-HLA genes display different associations with each
subset. So far, many genome wide association studies (GWAS) of
RA and ACPA-positive RA have been performed, and more than
twenty genes or loci have been shown to be susceptibility loci [25–
38]. However, no GWAS studies have detected susceptibility genes
for ACPA-negative RA with genome-wide significance [39]. This
is probably due to the relatively small number of patients studied,
but it might be overcome by stratifying ACPA-negative RA
patients into RF-positive and RF-negative subsets. Since RA
susceptibility genes usually cross ethnic boundaries [40], global




This study was approved by the local ethical committees at each
institution, namely, Kyoto University Graduate School and
Faculty of Medicine, Ethics Committee, Tokyo Women’s Medical
University Genome Ethics Committee, and the ethics committee
of RIKEN, and written informed consent was obtained from all
patients.
Study Subjects
DNA samples were collected from ACPA-negative RA patients
at Kyoto University Hospital, Tokyo Women’s Medical University
[41], and RIKEN with the support of BioBank Japan. All patients
were Japanese and had been diagnosed by rheumatologists
Table 4. Logistic regression analysis of HLA-DRB1 alleles with
ACPA-positive RF-positive RA and ACPA-positive RF-negative
RA.
ACPA(+)RF(+)RA ACPA(+)RF(2)RA
HLA-DRB1 p* OR (95%CI)* p* OR (95%CI)*
SE ,2610216 3.21 (2.72–3.78) ,2610216 3.03 (2.33–3.94)
*09:01 2.461029 1.83 (1.5–2.25) 0.0035 1.67 (1.17–2.37)
*p-values and odds ratios in logistic regression analysis using SE and HLA-
DRB1*09:01.
doi:10.1371/journal.pone.0040067.t004






allele (%) p OR (95%CI)
*09:01 169 (18.9%) 139 (13.7%) 0.0018 1.47 (1.15–1.88)
*04:05 153 (17.2%) 126 (12.4%) 0.0034 1.46 (1.13–1.89)
*08:02 24 (2.7%) 52 (5.1%) 0.0068 0.51 (0.31–0.84)
*14:06 8 (0.9%) 21 (2.1%) 0.037 0.43 (0.19–0.97)
SE 256 (28.7%) 234 (23.0%) 0.0047 1.35 (1.09–1.65)
DR14 78 (8.7%) 120 (11.8%) 0.028 0.72 (0.53–0.97)
DR8/DR8 6 (1.3%) 19 (3.7%) 0.021 0.35 (0.14–0.89)
doi:10.1371/journal.pone.0040067.t003
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according to the 1987 American College of Rheumatology revised
criteria for RA [42]. The control DNA samples were collected at
Aichi Cancer Center Hospital, the DNA banks of the Pharma
SNP Consortium [43], and HLA laboratory. A more detailed
description of the collection procedure was given in a previous
study [14]. We performed association studies using similar study
design of the two collections to our previous study; namely,
collection 1 for 456 ACPA-negative RA and 1508 healthy subjects,
and collection 2 for 501 ACPA-negative RA and 500 healthy
people. RF data were available for 453 out of 456 cases in
collection 1 and all of 501 cases in collection 2. 179 patients were
RF-positive in collection 1 and 267 patients were RF-positive in
collection 2. We also collected DNA samples from 531 ACPA-
positive RF-positive RA patients at Kyoto University Hospital and
154 ACPA-positive RF-negative RA patients at Kyoto University
and Tokyo Women’s Medical University.
ACPA Detection
The MESACUP CCP ELISA kit (Medical and Biological
Laboratories Co., Ltd, Nagoya, Japan) was used to detect 2nd
generation ACPA in each RA patient, according to the
manufacturer’s instructions. A cut-off value of 4.5 U/ml was used
to define ACPA positivity.
RF Detection
The serum RF concentrations of samples in collection 1 were
quantified using a latex agglutination turbidimetric immunoassay.
An ELISA assay was used to determine the RF levels of samples in
collection 2. When multiple values for RF had been obtained at
different visits, we used the maximum RF value for each patient.
The cut off values of each detection kit in each hospital were
employed.
HLA-DRB1 Genotyping
The HLA-DRB1 typing methods were previously described
[14]. Briefly, the WAKFlow system or the AlleleSEQR HLA-
DRB1 typing kit (Abbott, Tokyo, Japan) was used for the HLA-
DRB1 typing. The following HLA-DRB1 alleles were classified as
belonging to the SE: DRB1*01:01, *01:02, *04:01, *04:04, *04:05,
*04:08, *04:10, *04:13, *04:16, *10:01, *14:02, and *14:06.
Statistical Analysis
The frequency of each allele or diplotype was compared among
the ACPA-negative RF-positive RA, ACPA-negative RF-negative
RA patients, and the healthy controls in each set and combined set
using the chi-square test or Fisher’s exact test. The same analyses
were performed in ACPA-positive RA patients classified according
to their RF possession. Ninety-five percent confidence intervals
(CI) for the OR were also calculated. Logistic regression analysis
was used to evaluate the effects of each allele by adjusting for the
influence of strongly-associated alleles. Single alleles were regarded
as significant when they showed p-values of less than 0.0026 in a
combined study, which is obtained by Bonferroni’s correction. For
diplotype analyses, we regarded 0.025 as the cut off level for
significance because we performed just two tests. All statistical
analyses were performed using the R statistic system (http://www.
R-project.org) or SPSS (version 18).
Supporting Information
Figure S1 Dosage effects of HLA-DRB1*04:05 and
*09:01 alleles on ACPA-negative RF-positive RA suscep-
tibility. Each column represents the odds ratio for developing
ACPA-negative RF-positive RA associated with possessing one
(red column) or two (green column) alleles of HLA-DRB1*04:05
or *09:01.
(TIF)
Table S1 Logistic regression analysis of associated alleles with
ACPA-negative RF-positive RA. *p-values and odds ratios in
logistic regression analysis using the six alleles listed above.
(DOC)
Table S2 Association between HLA-DR14 and ACPA-negative
RF-negative RA.
(DOC)
Table S3 Logistic regression analysis of associated alleles with
ACPA-negative RF-negative RA. *p-values and odds ratios in
logistic regression analysis using HLA-DR14 and three HLA-
DRB1 alleles listed above.
(DOC)
Table S4 Association of HLA-DRB1 with ACPA-negative RA
erosive subsets. a)Total allele number is 268. b)Total allele number
is 212.
(DOC)
Table S5 Logistic regression analysis of assoicated alleles with
ACPA-negative RF-positive RA, compared with ACPA-negative
RF-negative RA. *p-values and odds ratios in logistic regression
analysis using HLA-DRB1*09:01, *04:05, and HLA-DR14.
a)HLA-DRB1 alleles which showed p,0.05 in Table 3 were used
for analysis.
(DOC)
Table S6 Comparison between ACPA-positive RF-positive RA
and ACPA-positive RF-negative RA. a) Alleles with frequency
more than 1% in any groups are shown.
(DOC)
Figure 1. Summary of the HLA-DRB1 alleles associated with
ACPA-negative RA and ACPA-positive RA. The relationships
between the RF-positive and RF-negative subsets of ACPA-negative
and ACPA-positive RA in terms of their associations with HLA-DRB1
alleles are illustrated. While the two subsets of ACPA-positive RA seem
to share most associations with HLA-DRB1, the two ACPA-negative RA
subsets possess specific alleles and HLA-DRB1 diplotypes. The
underlined alleles are protective alleles.
doi:10.1371/journal.pone.0040067.g001
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